Trial Drug Shows Promise for Rare Kidney Disease, Journal Reports

Trial Drug Shows Promise for Rare Kidney Disease, Journal Reports
AI-generated illustration

A phase 3 clinical trial of ravulizumab in patients with IgA nephropathy has published interim results in the New England Journal of Medicine.

The New England Journal of Medicine has posted interim findings from the I CAN trial, a phase 3 study testing ravulizumab as a treatment for IgA nephropathy (a condition in which antibody deposits cause progressive scarring of the kidney’s tiny filters). The interim analysis was published online on 23 October 2026 in the journal’s original research section.

According to the journal, patients given ravulizumab had a greater reduction in proteinuria (excess protein in the urine, which doctors use as a measure of kidney damage) than those given a placebo. The journal has also published a research summary alongside the trial results.

IgA nephropathy is the most common form of primary glomerulonephritis (inflammation of the kidney filters) worldwide. It can lead to chronic kidney disease and, in some cases, kidney failure over time.

Ravulizumab is a complement inhibitor — a drug that blocks part of the immune system’s signalling chain thought to drive the kidney damage seen in IgA nephropathy. The New England Journal of Medicine published the interim analysis under its nephrology category.

The I CAN trial is ongoing. Because only interim data are available, the full picture of the drug’s long-term safety and effectiveness has yet to emerge.

—